You are here

Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

Last updated on December 17, 2017

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Palo Alto, California, United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Aging, Frail Older Adults
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65-84 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

65-84 years old, BMI Activities of Daily Living (per Nagy's), or 2 or more falls in prior 2 years

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Significant history or symptoms of acute medical conditions, currently in an exercise
program, pain or other conditions that would prevent participating in exercise testing

NCT00527046
Pfizer
Terminated
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Healthy Adults
NCT02767089
All Genders
18+
Years
Kalamazoo, Michigan
Aging, Frail Older Adults
NCT00527046
All Genders
65+
Years
Multiple Sites
Frail Elderly
NCT00249704
All Genders
75+
Years
Multiple Sites
Effects Of An Oral Growth Hormone Secretagogue In Older Functionally Limited Adults
A Randomized, Double Blind, Placebo Controlled, Five Parallel Group Study Of The Effect Of CP-424,391 On Physical Performance And Body Composition In Older Subjects
A 24-month, placebo controlled, double dummy, parallel-design outpatient trial in generally healthy elderly men and women who are at risk of becoming frail.
Not Provided
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
  • Aging
  • Frail Older Adults
Drug: CP-424,391
Not Provided
White HK, Petrie CD, Landschulz W, MacLean D, Taylor A, Lyles K, Wei JY, Hoffman AR, Salvatori R, Ettinger MP, Morey MC, Blackman MR, Merriam GR; Capromorelin Study Group. Effects of an oral growth hormone secretagogue in older adults. J Clin Endocrinol Metab. 2009 Apr;94(4):1198-206. doi: 10.1210/jc.2008-0632. Epub 2009 Jan 27.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
396
October 2001
October 2001   (Final data collection date for primary outcome measure)

Inclusion Criteria:

65-84 years old, BMI < 30, at risk for functional decline based on SF-36, Instrumental Activities of Daily Living (per Nagy's), or 2 or more falls in prior 2 years

Exclusion Criteria:

Significant history or symptoms of acute medical conditions, currently in an exercise program, pain or other conditions that would prevent participating in exercise testing

Sexes Eligible for Study: All
65 Years to 84 Years   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00527046
A257-102
Not Provided
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now